Angiodynamics (ANGO) Equity Average (2016 - 2025)
Angiodynamics (ANGO) has disclosed Equity Average for 15 consecutive years, with $177.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 7.35% year-over-year to $177.6 million, compared with a TTM value of $177.6 million through Nov 2025, down 7.35%, and an annual FY2025 reading of $194.3 million, down 33.45% over the prior year.
- Equity Average was $177.6 million for Q4 2025 at Angiodynamics, down from $180.9 million in the prior quarter.
- Across five years, Equity Average topped out at $454.6 million in Q1 2021 and bottomed at $177.6 million in Q4 2025.
- Average Equity Average over 5 years is $335.7 million, with a median of $402.9 million recorded in 2023.
- The sharpest move saw Equity Average rose 0.86% in 2023, then tumbled 53.76% in 2024.
- Year by year, Equity Average stood at $434.2 million in 2021, then dropped by 5.33% to $411.0 million in 2022, then grew by 0.86% to $414.5 million in 2023, then tumbled by 53.76% to $191.7 million in 2024, then fell by 7.35% to $177.6 million in 2025.
- Business Quant data shows Equity Average for ANGO at $177.6 million in Q4 2025, $180.9 million in Q3 2025, and $184.4 million in Q2 2025.